Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02691494
Recruitment Status : Completed
First Posted : February 25, 2016
Last Update Posted : February 11, 2019
Sponsor:
Information provided by (Responsible Party):
AbbVie

Brief Summary:
This study seeks to evaluate the efficacy, safety and tolerability of elagolix alone and in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Condition or disease Intervention/treatment Phase
Uterine Fibroids Heavy Menstrual Bleeding Drug: Elagolix Drug: Placebo for Estradiol/Norethindrone Acetate Drug: Estradiol/Norethindrone Acetate Drug: Placebo for Elagolix Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 378 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Actual Study Start Date : February 3, 2016
Actual Primary Completion Date : February 14, 2018
Actual Study Completion Date : January 23, 2019


Arm Intervention/treatment
Placebo Comparator: Placebo
Participants receiving placebo for both elagolix and estradiol/norethindrone acetate.
Drug: Placebo for Estradiol/Norethindrone Acetate
Placebo for 6-month Treatment

Drug: Placebo for Elagolix
Placebo for 6-month Treatment

Experimental: Elagolix+Estradiol/Norethindrone Acetate
Participants receiving elagolix and estradiol/norethindrone acetate.
Drug: Elagolix
Elagolix for 6-month Treatment
Other Names:
  • ABT-620
  • Elagolix Sodium

Drug: Estradiol/Norethindrone Acetate
Estradiol/Norethindrone Acetate for 6-month Treatment
Other Name: E2/NETA

Experimental: Elagolix
Participants receiving elagolix and placebo for estradiol/norethindrone acetate.
Drug: Elagolix
Elagolix for 6-month Treatment
Other Names:
  • ABT-620
  • Elagolix Sodium

Drug: Placebo for Estradiol/Norethindrone Acetate
Placebo for 6-month Treatment




Primary Outcome Measures :
  1. Percentage of Responders With Menstrual Blood Loss (MBL) Volume of < 80 mL at Final Month and >= 50% Reduction in MBL Volume [ Time Frame: From Month 0 (Baseline) to Final Month of Treatment Period (up through 6 months) ]
    Participant who prematurely discontinues study drug due to "lack of efficacy," "requires surgery or invasive intervention for treatment of uterine fibroids," or adverse events will be considered as a non-responder regardless whether she meets the two aforementioned responder criteria or not. Assessed using alkaline hematin methodology


Secondary Outcome Measures :
  1. Change from Baseline in MBL volume [ Time Frame: From Month 0 (Baseline) to Month 1, Month 3, Month 6 and Final Month (the last 28 days prior to and including the Reference Day) ]
    Baseline MBL volume will be defined as the mean of total MBL volume from all the qualified menstrual cycles during the Screening Period, in which the total MBL volume is from all validated and non-validated sanitary products and the MBL volume of validated sanitary products only (excluding non-validated sanitary products) is greater than 80 mL.

  2. Percentage of Participants with Suppression of Bleeding [ Time Frame: At Final Month (the last 28 days prior to and including the Reference Day) ]
    Suppression of bleeding is defined as having 0 days of bleeding (spotting is allowed) during the Final Month with the interval starting from Study Day 11.

  3. Percentage of Participants with Baseline hemoglobin <= 10.5 g/dL who have an increase in hemoglobin > 2 g/dL [ Time Frame: At Month 6 ]
    The increase in hemoglobin is assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 51 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is a premenopausal female at the time of Screening.
  • Subject has a diagnosis of uterine fibroids documented by a Pelvic Ultrasound (TAU, TVU).
  • Subject has HMB associated with uterine fibroids as evidenced by MBL > 80 mL during each of two screening menses as measured by the alkaline hematin method.
  • Subject has negative urine and/or serum pregnancy test in Screening and just prior to first dose.
  • Subject has an adequate endometrial biopsy performed during Screening, the results of which show no clinically significant endometrial pathology.

Exclusion Criteria:

  • Subject has screening pelvic ultrasound or SIS results that show a clinically significant gynecological disorder.
  • Subject has history of osteoporosis or other metabolic bone disease.
  • Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis.
  • Subject has a history of major depression or post-traumatic stress disorder (PTSD) within 2 years of screening, OR a history of other major psychiatric disorder at any time (e.g., schizophrenia, bipolar disorder).
  • Subject is using any systemic corticosteroids for over 14 days within 3 months prior to Screening or is likely to require treatment with systemic corticosteroids during the course of the study. Over the counter and prescription topical, inhaled, intranasal or injectable (for occasional use) corticosteroids are allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02691494


  Show 103 Study Locations
Sponsors and Collaborators
AbbVie
Investigators
Layout table for investigator information
Study Director: AbbVie Inc. AbbVie

Additional Information:
Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT02691494     History of Changes
Other Study ID Numbers: M12-817
First Posted: February 25, 2016    Key Record Dates
Last Update Posted: February 11, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
URL: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AbbVie:
Elagolix
Elagolix Sodium
Heavy uterine bleeding
Heavy menstrual bleeding (HMB)
Leiomyomata
Menorrhagia
ABT-620
Elagolix + E2/NETA (Elagolix + Norethindrone acetate)
Additional relevant MeSH terms:
Layout table for MeSH terms
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol
Polyestradiol phosphate
Leiomyoma
Myofibroma
Menorrhagia
Hemorrhage
Pathologic Processes
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Connective Tissue
Connective Tissue Diseases
Uterine Hemorrhage
Uterine Diseases
Genital Diseases, Female
Menstruation Disturbances
Norethindrone
Norethindrone Acetate
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic
Contraceptives, Oral